



# Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma

## SUPPLEMENTARY FIGURES



**Supplementary Figure 1: RPPA protein array analysis of glioma cells and GICs treated with DS7423.** Color bars indicate an increase (red) or decrease (green) of signaling proteins following DS7423 treatment (200 nmol/L, 24 hours). Differential changes in signaling proteins between untreated and treated GICs were selected with  $P < 0.05$ . Western Blot showing DS inhibits PI3K and mTORC1 and mTORC2 mediated activity.

LN229



**Supplementary Figure 2: DS was ineffective in a LN229 tumor bearing mice and had no effect in median survival of animals clearly demonstrating that DS was ineffective in PTEN/PI3K wild type background. The study was repeated twice.**